Sign in Subscribe

SERB Acquires Y-mAbs: Rare Oncology Expansion

SERB Pharmaceuticals acquires Y-mAbs for $412M, gaining DANYELZA, an FDA-approved treatment for high-risk neuroblastoma, enhancing rare oncology portfolio.

SERB Acquires Y-mAbs: Rare Oncology Expansion
Credit: Dr. Maria Tsokos, National Cancer Institute

This post is for paying subscribers only

Already have an account? Sign in.